A faster, more accurate way to understand whether a treatment is having an effect
Inclusion body myositis has long confounded medicine not for want of effort, but for want of the right instruments — the disease moves slowly, and so too have the tools used to study it. Now, a partnership between the Snow Centre for Immune Health and the Royal Melbourne Hospital is attempting to reframe the problem entirely, building a biomarker platform that could reveal whether a therapy is working in weeks rather than years. The collaboration, anchored by clinician-scientist Dr Jessica Day and the Walter and Eliza Hall Institute, marks the first serious attempt to give IBM research the speed it has always lacked — and with it, the first real hope for people watching their strength quietly disappear.
- Inclusion body myositis strips patients of strength, mobility and independence with no treatment available to slow or stop its progression — a medical silence that has persisted for decades.
- Traditional clinical trials have failed IBM research not through lack of promise but through blunt measurement tools that take too long to detect whether any therapy is actually working.
- A new pilot clinical trial is now testing an immune-targeting therapy while simultaneously building a biomarker platform designed to detect meaningful biological change far earlier than existing methods allow.
- The Snow Centre, WEHI and Royal Melbourne Hospital are combining clinical expertise, immunology research and advanced technology infrastructure in a model designed to accelerate the entire IBM research pipeline — not just this single trial.
- If the biomarker platform succeeds, it becomes a permanent tool for all future IBM research, potentially compressing the timeline to the field's first effective treatment by years.
Inclusion body myositis takes things slowly — strength first, then mobility, then independence — and for decades, medicine has had no answer. The disease's gradual pace has been its own defence: traditional measures like strength tests and mobility assessments move too slowly to tell researchers whether a new therapy is working, causing trials to drag on and promising treatments to be abandoned not because they fail, but because the tools to judge them are too blunt.
A new collaboration between the Snow Centre for Immune Health and the Royal Melbourne Hospital is now attempting to change that. Dr Jessica Day, a rheumatologist at Royal Melbourne and Senior Research Officer at the Walter and Eliza Hall Institute, has partnered with Snow Centre scientists to build a research platform capable of detecting whether a therapy is working in weeks or months rather than the year or more traditional trials require. The key is biomarkers — measurable biological signals that can serve as early indicators of whether a treatment is having any effect.
The collaboration is launching a pilot clinical trial targeting the immune pathways believed to drive IBM, but the deeper innovation is the measurement infrastructure being built around it. By combining clinical knowledge from the hospital, immunology research from WEHI, and the Snow Centre's advanced technological capabilities, the team aims to create tools that outlast any single trial. Dr Day has described the combination of expertise as what makes the project possible at all.
Professor Jason Tye-Din, director of the Snow Centre, framed the stakes plainly: people living with IBM have waited far too long. The Snow Centre's first formal call for research partnerships specifically sought projects that would deliver meaningful progress in immune health — and this one was selected because it addresses not just the absence of a drug, but the absence of a way to know whether any drug is working.
For IBM patients, this represents the first real momentum the field has seen in years. Whether or not this particular therapy succeeds, the biomarker platform itself becomes a lasting resource — a tool that could accelerate every treatment candidate that follows, and bring the field's first effective therapy closer than anyone has previously been able to imagine.
Inclusion body myositis steals from people slowly. It takes their strength first—the ability to climb stairs, to lift a cup, to stand from a chair. Then it takes their mobility. Eventually, it takes their independence. And there is nothing doctors can do to stop it.
For decades, this progressive muscle disease has defeated research efforts. The problem is not a lack of will but a lack of visibility. IBM progresses so gradually that traditional measures—strength tests, mobility assessments—move at a crawl. By the time a researcher can detect whether a new therapy is actually working, months have passed. Trials drag on. Promising treatments get abandoned not because they fail, but because the tools to measure success are too blunt.
Now a collaboration between the Snow Centre for Immune Health and the Royal Melbourne Hospital is attempting to change that equation. Dr Jessica Day, a rheumatologist at the Royal Melbourne Hospital and Senior Research Officer at the Walter and Eliza Hall Institute, has partnered with Snow Centre scientists to build something new: a research platform designed to reveal whether a therapy is working far earlier than existing methods. The approach hinges on identifying biomarkers—measurable biological signals that can serve as early warning systems or early victories, depending on what they show.
The collaboration is launching a pilot clinical trial testing a therapy that targets the immune pathways believed to drive IBM. This is the first concrete step. But the real innovation lies in how they will measure what happens next. By combining deep clinical knowledge from the hospital, cutting-edge immunology research from WEHI, and advanced technological infrastructure from the Snow Centre, the team aims to detect meaningful change in weeks or months rather than the year or more that traditional trials require.
Dr Day frames the work in practical terms. "This combination of expertise and infrastructure makes this ambitious project possible," she said. "It gives us a faster, more accurate way to understand whether a treatment is having an effect – something that could transform the search for real therapies." The implication is clear: faster detection means faster iteration, which means the first effective IBM treatment could arrive years sooner than it otherwise would.
Professor Jason Tye-Din, director of the Snow Centre, emphasizes the human stakes. "People living with IBM have waited far too long for progress," he said. The Snow Centre, in its first formal call for research partnerships, specifically invited clinician-scientists from partner organizations to codesign projects that would deliver meaningful improvements in immune health. This project was selected because it addresses what the field has lacked: not just a new drug candidate, but a new way of knowing whether a drug candidate is working.
The collaboration represents a shift in how research gets organized around rare diseases. Rather than researchers in isolation pursuing incremental gains, this model brings together the people who treat patients, the scientists who study disease mechanisms, and the technologists who can measure what was previously invisible. The result is a platform designed not just to test one therapy, but to accelerate the entire pipeline of IBM research that follows.
For people living with IBM—watching their bodies change, their options limited—this represents the first real momentum the field has seen in years. Whether this particular therapy succeeds or fails, the biomarker platform itself becomes a tool for everyone who comes after. The disease will not wait. But now, at least, the research can move faster.
Citas Notables
This combination of expertise and infrastructure makes this ambitious project possible. It gives us a faster, more accurate way to understand whether a treatment is having an effect.— Dr Jessica Day, rheumatologist at Royal Melbourne Hospital
People living with IBM have waited far too long for progress. This project could speed up the development of the first-ever effective treatment for IBM.— Professor Jason Tye-Din, Snow Centre Director
La Conversación del Hearth Otra perspectiva de la historia
Why has IBM been so hard to treat? Is it just that we don't understand the disease well enough?
That's part of it, but the bigger problem is measurement. IBM progresses so slowly that traditional strength tests take months to show change. Researchers can't tell if a therapy is working until it's too late to adjust course.
So the biomarker approach is really about speed—getting an answer faster?
Exactly. If you can measure immune activity or tissue changes at the cellular level, you know within weeks whether a therapy is having an effect. That transforms the entire research timeline.
What makes this collaboration different from other IBM research efforts?
It's the combination. You have the clinicians who see patients every day, the immunologists who understand the disease mechanisms, and the technologists with the infrastructure to measure things that were invisible before. That's rare.
If this works, what happens next?
The biomarker platform becomes a tool for everyone. Future therapies can be tested faster. The field accelerates. And patients stop waiting.
Is there a risk this particular therapy doesn't work?
Of course. But that's not really the point. Even if it fails, the platform succeeds. The research infrastructure stays in place. The next therapy gets tested faster.
So the real innovation isn't the drug—it's the way of measuring?
That's it. The drug is just the first test of a new system.